[ad_1]
A recent study on monitoring the level of cisplatin in liver cancer cells reported by researchers at the Graduate School of Medical and Dental Sciences, University of Niigata, Japan and their collaborators at Niigata Medical Center, Uonuma Institute of Community Medicine Niigata University Hospital, Niigata City General Hospital, Saiseikai Niigata Hospital and Kashiwazaki General Hospital and Medical Center provide a ray of hope for healthcare professionals.
[ad_2]
The results were recently published in the prestigious Scientific reports diary of Nature. The multidisciplinary research team identified the most abundant fat protein 2 (APM2) as a potential marker to indicate the allowable level of the drug. They experimentally studied liver and gastro-cancer cells and compared the variation in protein concentration in the presence and absence of the chemo drug.
Source link
